Article
Oncology
Lijie Zhai, April Bell, Erik Ladomersky, Kristen L. Lauing, Lakshmi Bollu, Brenda Nguyen, Matthew Genet, Miri Kim, Peiwen Chen, Xinlei Mi, Jennifer D. Wu, Matthew J. Schipma, Brian Wray, John Griffiths, Richard D. Unwin, Simon J. Clark, Rajesh Acharya, Riyue Bao, Craig Horbinski, Rimas Lukas, Gary E. Schiltz, Derek A. Wainwright
Summary: This study reveals that nonenzymatic tumor cell IDO activity decreases survival and increases CFH and FHL-1 expression in human GBM independent of Trp metabolism. The increased intra-tumoral CFH and FHL-1 levels are associated with poorer survival in glioma patients. Like IDO effects, GBM cell FHL-1 expression increases intratumoral Treg and myeloid-derived suppressor cells while decreasing overall survival in mice with GBM, providing a new therapeutic target for GBM patients.
CLINICAL CANCER RESEARCH
(2021)
Review
Materials Science, Biomaterials
Jia Xiong, Hui Wang, Qingqing Wang
Summary: Cancer is the result of conflict between the host immune system and cancer cells, with immune cells and tumor cells interacting within the tumor microenvironment influencing tumor progression and metastasis. Studies have shown that tumor-infiltrating myeloid cells can accelerate tumor growth, induce angiogenesis, metastasis, and therapy resistance.
Review
Immunology
Michael Platten, Mirco Friedrich, Derek A. Wainwright, Verena Panitz, Christiane A. Opitz
Summary: Tryptophan metabolism plays a crucial role in cancer immunotherapy, particularly in promoting malignant phenotypes and immunosuppressive tumor microenvironments in brain tumors. Recent research has advanced our understanding of the role of tryptophan metabolism and its metabolites in regulating brain function and neuronal integrity, as well as potential therapeutic targets for glioma treatment.
CURRENT OPINION IN IMMUNOLOGY
(2021)
Review
Immunology
Claudia Giannotta, Federica Autino, Massimo Massaia
Summary: Myeloid derived suppressor cells (MDSC) have significant roles in regulating immune homeostasis and immune responses, especially in cancer. MDSC interact with cancer cells in the tumor microenvironment through various mechanisms such as producing soluble factors, expressing inhibitory molecules, rewiring metabolism, and releasing exosomes. The relationship between MDSC and tumor cells leads to immune evasion and cancer growth. In multiple myeloma (MM), MDSC play a major role in creating a tumor-promoting microenvironment. This minireview discusses the interplay between MDSC and MM microenvironment, as well as potential strategies to target MDSC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Nanoscience & Nanotechnology
Yonghui Liu, Zhaoyu Wang, Fan Yu, Mingjing Li, Haomiao Zhu, Kun Wang, Meng Meng, Wei Zhao
Summary: This study aimed to enhance the immune effect of MUC1 glycopeptide antigen-based antitumor vaccines by developing novel adjuvants and carriers. The constructed vaccines showed significant antibody response, specific binding with MUC1 positive cells, and induction of MUC1-specific CTLs. Overall, the use of alpha-GalCer adjuvant and antigen on gold nanoparticles offers a potential strategy to improve antitumor response in cancer immunotherapy.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Multidisciplinary Sciences
Kevin Alicea-Torres, Emilio Sanseviero, Jun Gui, Jinyun Chen, Filippo Veglia, Qiujin Yu, Laxminarasimha Donthireddy, Andrew Kossenkov, Cindy Lin, Shuyu Fu, Charles Mulligan, Brian Nam, Gregory Masters, Fred Denstman, Joseph Bennett, Neil Hockstein, Agnieszka Rynda-Apple, Yulia Nefedova, Serge Y. Fuchs, Dmitry Gabrilovich
Summary: Type I interferon receptor signaling serves as a universal mechanism restricting MDSC suppressive activity, with downregulation of IFNAR1 required for activation of immune suppressive properties in MDSC. Modulating IFNAR1 undermines MDSC suppressive activity and has potent anti-tumor effects.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Nicola Cotugno, Enrica Franzese, Giulia Angelino, Donato Amodio, Erminia Francesca Romeo, Francesca Rea, Simona Faraci, Renato Tambucci, Elisa Profeti, Emma Concetta Manno, Veronica Santilli, Gioacchino Andrea Rotulo, Chiara Pighi, Chiara Medri, Elena Morrocchi, Luna Colagrossi, Giuseppe Rubens Pascucci, Diletta Valentini, Alberto Villani, Paolo Rossi, Paola De Angelis, Paolo Palma
Summary: Patients with Inflammatory Bowel Disease (IBD) show good safety and immunogenicity following SARS-CoV-2 mRNA vaccination, but those receiving anti-TNFoc treatment have lower antibody titers.
Article
Biochemistry & Molecular Biology
Sabina Kaczanowska, Daniel W. Beury, Vishaka Gopalan, Arielle K. Tycko, Haiying Qin, Miranda E. Clements, Justin Drake, Chiadika Nwanze, Meera Murgai, Zachary Rae, Wei Ju, Katherine A. Alexander, Jessica Kline, Cristina F. Contreras, Kristin M. Wessel, Shil Patel, Sridhar Hannenhalli, Michael C. Kelly, Rosandra N. Kaplan
Summary: By utilizing genetically engineered myeloid cells to deliver IL-12, immune suppression in the premetastatic niche can be reversed, resulting in improved survival and reduced metastatic and primary tumor burden in tumor-bearing mice.
Article
Pharmacology & Pharmacy
Congcong Li, Chaoxi Chen, Yucai Wei, Min Tan, Shuo Zhai, Juebo Zhao, Lu Wang, Tao Dai
Summary: The study focused on modifying SP-gamma-CD-MOF as animal vaccine adjuvants, demonstrating excellent biocompatibility in vitro and in vivo. Loaded with ovalbumin, SP-gamma-CD-MOF induced high antigen-specific IgG titers and cytokine secretion, while also enhancing spleen cell proliferation and activating and maturing BMDCs. This research highlights the potential of SP-gamma-CD-MOF in vaccine adjuvants and offers a new approach for their development.
Article
Fisheries
Yu-Ming Gong, Xue-Feng Wei, Guo-Qing Zhou, Ming -Zhu Liu, Peng-Fei Li, Bin Zhu
Summary: In this study, a biomimetic nanodelivery system using modified erythrocyte membrane as a DNA vaccine carrier was constructed. The nanoparticles showed sustained and efficient expression of plasmid DNA in muscle and spleen tissue. Immunization of tilapia with the vaccine resulted in high levels of serum antibody production and immune-related gene expression. The vaccine also provided high protection against TiLV challenge.
Article
Pharmacology & Pharmacy
Alexis A. Ellis, Sean M. Geary, Aliasger K. Salem
Summary: Heterologous prime-boost vaccines consisting of a microparticle formulation and an adenoviral vaccine were used in this study to investigate their effect on antigen-specific immune responses. The results showed that this prime-boost vaccine significantly enhanced cellular immune responses and conferred a significant survival advantage in a prophylactic animal tumor model.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Chemistry, Applied
Qian Wang, Hao Jiang, Hongli Zhang, Weiqiao Lu, Xiao Wang, Wenfeng Xu, Jia Li, Youjing Lv, Guoyun Li, Chao Cai, Guangli Yu
Summary: This study proposes a novel strategy of antibody-beta-glucan conjugates (AGC) to enhance the antitumor immune response to immune checkpoint blockade (ICB) therapy. AGC demonstrated powerful tumor suppression and promoted interaction between tumor cells and dendritic cells (DCs), thereby enhancing immunotherapeutic benefits.
CARBOHYDRATE POLYMERS
(2024)
Article
Immunology
Yue Lou, Peng Peng, Shicheng Wang, Junjun Wang, Peishan Du, Zelu Zhang, Jiamin Zheng, Ping Liu, Lisa X. Xu
Summary: Combining all-trans retinoid acid (ATRA) with cryo-thermal therapy was found to improve the long-term survival rate of mice. The combination therapy promoted the maturation of MDSCs and inhibited the expression of their suppressive molecules, while efficiently decreasing glutamine and fatty acid metabolism.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
I-Tsang Chiang, Yuan-Hao Lee, Zhao-Lin Tan, Fei-Ting Hsu, Hsi-Feng Tu
Summary: Combination therapy with regorafenib and anti-PD-L1 can enhance anti-tumor immune response and suppress immunosuppression in oral squamous cell carcinoma (OSCC). This finding contributes to the development of more effective treatment strategies for OSCC.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
S. Elizabeth Franks, Kellsye P. Fabian, Ginette Santiago-Sanchez, Benjamin Wolfson, James W. Hodge
Summary: Combining immune therapy targeting multiple immunosuppressive pathways has shown significant antitumor activity and survival benefit in mouse tumor models, suggesting the potential for improved cancer treatment strategies.
Review
Immunology
Mads Hald Andersen
Summary: Identifying and characterizing tumor antigens are crucial for developing anti-cancer immunotherapy. Traditional tumor-associated antigens (TAAs) are mainly expressed in tumor cells, while tumor-specific antigens (TSAs) are unique to tumor cells. Recent studies have focused on patient-specific neoantigens, which are highly immunogenic due to their absence in normal tissues. In addition, the discovery of anti-regulatory T cells (anti-Tregs) has led to the identification of tumor microenvironment antigens (TMAs) that can be targeted for immunotherapy. TMAs not only directly attack tumor cells but also modulate the tumor microenvironment, making it more immunocompetent and hostile to tumors. Unlike TAAs and TSAs, TMAs are also expressed in non-transformed cells, providing the opportunity to affect tumors with low levels of surface human leukocyte antigen (HLA) expression. This review discusses the characteristics, differences, and advantages of TMAs compared to traditional tumor antigens and highlights the potential of using TMAs in immune modulatory vaccines as a promising approach to immunotherapy.
SEMINARS IN IMMUNOPATHOLOGY
(2023)
Article
Immunology
Cathrine Lund Lorentzen, Evelina Martinenaite, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Sofie Kirial Mork, Ayako Wakatsuki Pedersen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane
Summary: The clinical trial of arginase-1 peptide vaccine in patients with treatment-refractory solid tumors demonstrated the safety and efficacy of the vaccine in inducing peptide-specific immune responses. Additionally, some patients achieved stable disease during treatment, showcasing the potential of arginase-1 vaccination as a therapeutic approach.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Ines Lecoq, Katharina L. Kopp, Marion Chapellier, Panagiotis Mantas, Evelina Martinenaite, Maria Perez-Penco, Lars Ronn Olsen, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen
Summary: This study identified CCL22 as a potential target for immunotherapy by showing that vaccination with CCL22-derived peptides induced specific T-cell responses and had anti-tumor effects in mouse models. The vaccination also modulated the immune cell composition in the tumor microenvironment, increasing the infiltration of CD8+ cells and M1 macrophages, and altering the immune cell ratios. These findings provide a rationale for the development of CCL22-targeting immunotherapy in cancer.
Editorial Material
Infectious Diseases
Mads Hald Andersen
Article
Oncology
Arianna Draghi, Mario Presti, Agnete W. P. Jensen, Christopher A. Chamberlain, Benedetta Albieri, Anne-Christine K. Rasmussen, Mads H. Andersen, Michael D. Crowther, Inge Marie Svane, Marco Donia
Summary: Our study demonstrates that exploiting tumor-specific cytotoxic CD4(+) TILs could help overcome resistance to ICB mediated by IFN gamma-signaling loss in MHCIIconst(+) melanomas.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Immunology
Mads Hald Andersen
SEMINARS IN IMMUNOPATHOLOGY
(2023)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Jacob Handlos Grauslund, Morten Orebo Holmstrom, Evelina Martinenaite, Thomas Landkildehus Lisle, Hannah Jorinde Glockner, Daniel El Fassi, Uffe Klausen, Rasmus E. J. Mortensen, Nicolai Jorgensen, Lasse Kjaer, Vibe Skov, Inge Marie Svane, Hans Carl Hasselbalch, Mads Hald Andersen
Summary: The study tested the safety and efficacy of dual vaccination with ARG1- and PD-L1-derived peptides in JAK2 V617F-mutated MPN patients. The vaccines were found to be safe and induced strong T-cell responses in all patients, indicating their potential as a treatment option.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Thomas Morgan Hulen, Christina Friese, Nikolaj Pagh Kristensen, Joachim Stoltenborg Granhoj, Troels Holz Borch, Marlies J. W. Peeters, Marco Donia, Mads Hald Andersen, Sine Reker Hadrup, Inge Marie Svane, Ozcan Met
Summary: Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) have shown to be highly effective immunotherapies for metastatic melanoma treatment. In this study, we investigated the changes in TIL qualities when the ex vivo microenvironment of intact tumor fragments were modulated with checkpoint inhibitors targeting PD-1 and CTLA-4. We found that unmodified TILs from CPI-resistant individuals could be produced, were terminally differentiated, and capable of responding to tumor. Furthermore, we confirmed the specificity of TILs to highly responding tumor antigens and identified the contribution of specific CD39(+)CD69(+) terminally differentiated populations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Rasmus Erik Johansson Mortensen, Morten Orebo Holmstrom, Thomas Landkildehus Lisle, Jane P. Hasselby, Gro L. Willemoe, Ozcan Met, Inge Marie Svane, Julia Johansen, Dorte L. Nielsen, Inna M. Chen, Mads Hald Andersen
Summary: This study investigated the significance of TGF-beta-specific T-cell immunity in patients with pancreatic cancer treated with ICI combined with radiotherapy. The results showed that patients with a strong TGF-beta-specific immune response had longer progression-free and overall survival compared to those with a weak or no response. It was also found that TGF-beta-specific T cells could recognize and enhance immune responses. Thus, combining TGF-beta vaccination with ICI/radiotherapy may benefit patients with pancreatic cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Cathrine Lund Lorentzen, Julie Westerlin Kjeldsen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane
Summary: Summary: This study presented the long-term follow-up results of the IDO/PD-L1 vaccine and nivolumab combination therapy in cohort A, showing promising efficacy with high overall response rates and durable responses. However, cohort B did not show significant clinical effects.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Lasse Kjaer, Vibe Skov, Morten Kranker Larsen, Tobias Idor Boklund, Morten Andersen, Maria Kefala, Trine A. Knudsen, Christina Schjellerup Eickhardt-Dalboge, Thomas Stiehl, Johanne Gudmand-Hoyer, Jordan Snyder, Morten Holmstrom, Mads H. Andersen, Johnny T. Ottesen, Christina Ellervik, Hans C. Hasselbalch
Summary: The initial diagnosis of overt myeloproliferative neoplasms (MPNs) occurs when symptoms or complications lead to a patient seeking medical attention. In some MPN subgroups like essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are the drivers of the disease. This study follows a healthy individual with a CALR mutation from initial identification as CALR clonal hematopoiesis of indeterminate potential (CHIP) to the diagnosis of pre-MF, providing insights into pre-diagnostic dynamics that may aid in early diagnosis and intervention in MPN patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Morten Orebo Holmstrom, Morten Andersen, Sofie Traynor, Shamaila Munir Ahmad, Thomas Landkildehus Lisle, Jacob Handlos Grauslund, Vibe Skov, Lasse Kjaer, Johnny T. Ottesen, Morten Frier Gjerstorff, Hans Carl Hasselbalch, Mads Hald Andersen
Summary: CALRmut specific T cells do not increase in the bone marrow after therapeutic cancer vaccination against mutant CALR, possibly due to a high burden of CALRmut cells compared to the number of effector T cells in the peripheral blood.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Hans Carl Hasselbalch, Peter Junker, Vibe Skov, Lasse Kjaer, Trine A. Knudsen, Morten Kranker Larsen, Morten Orebo Holmstroem, Mads Hald Andersen, Christina Jensen, Morten A. Karsdal, Nicholas Willumsen
